The efficacy and safety of the biosimilar interferon beta-1a Teberif® in patients with relapsing-remitting multiple sclerosis: data from a comparative international multicenter double-blind placebo-controlled randomized Phase III study

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

Yearbook of Neurology and Neurosurgery ◽

10.1016/s0513-5117(09)79049-0 ◽

2009 ◽

Vol 2009 ◽

pp. 99-103

Author(s):

O. Kantarci

Keyword(s):

Multiple Sclerosis ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Relapsing Remitting ◽

Randomised, double blind, placebo controlled study of interferon beta -1a in relapsing-remitting multiple sclerosis analysed by area under disability/time curves

Journal of Neurology Neurosurgery & Psychiatry ◽

10.1136/jnnp.67.4.451 ◽

1999 ◽

Vol 67 (4) ◽

pp. 451-456 ◽

Cited By ~ 18

Author(s):

C. Liu ◽

L. D Blumhardt

Keyword(s):

Multiple Sclerosis ◽

Interferon Beta ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Relapsing Remitting ◽

72-Week Safety and Tolerability of Dimethyl Fumarate in Japanese Patients with Relapsing-remitting Multiple Sclerosis: Analysis of the Randomised, Double Blind, Placebo-Controlled, Phase III APEX Study and its Open-Label Extension

Advances in Therapy ◽

10.1007/s12325-018-0788-8 ◽

2018 ◽

Vol 35 (10) ◽

pp. 1598-1611 ◽

Cited By ~ 9

Author(s):

Hirofumi Ochi ◽

Masaaki Niino ◽

Yasuhiro Onizuka ◽

Katsutoshi Hiramatsu ◽

Masakazu Hase ◽

...

Keyword(s):

Multiple Sclerosis ◽

Japanese Patients ◽

Dimethyl Fumarate ◽

Phase Iii ◽

Open Label ◽

Double Blind ◽

Double Blind Placebo ◽

Relapsing Remitting ◽

Open Label Extension ◽

Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis

Journal of Neurology Neurosurgery & Psychiatry ◽

10.1136/jnnp.2003.010090 ◽

2004 ◽

Vol 75 (5) ◽

pp. 706-710 ◽

Cited By ~ 80

Author(s):

O Andersen

Keyword(s):

Multiple Sclerosis ◽

Low Dose ◽

Interferon Beta ◽

Progressive Multiple Sclerosis ◽

Secondary Progressive Multiple Sclerosis ◽

Phase Iii ◽

Double Blind ◽

Double Blind Placebo ◽

Secondary Progressive ◽

Phase Iii Study

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial

Neurology ◽

10.1212/wnl.43.4.662 ◽

1993 ◽

Vol 43 (4) ◽

pp. 662-662 ◽

Cited By ~ 830

Author(s):

D. W. Paty ◽

D.K.B. Li ◽

◽

Keyword(s):

Multiple Sclerosis ◽

Interferon Beta ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Relapsing Remitting ◽

FP36-WE-03 MRI outcomes of short-course oral treatment with cladribine tablets for relapsing-remitting multiple sclerosis (RRMS) in the 96-week, phase III, double-blind, placebo-controlled CLARITY study

Journal of the Neurological Sciences ◽

10.1016/s0022-510x(09)70458-7 ◽

2009 ◽

Vol 285 ◽

pp. S114 ◽

Cited By ~ 1

Author(s):

G. Comi ◽

S. Cook ◽

G. Giovannoni ◽

K. Rammohan ◽

P. Rieckmann ◽

...

Keyword(s):

Multiple Sclerosis ◽

Oral Treatment ◽

Phase Iii ◽

Double Blind ◽

Double Blind Placebo ◽

Short Course ◽

Relapsing Remitting ◽

FP36-WE-02 Clinical outcomes of short-course oral treatment with cladribine tablets for relapsing-remitting multiple sclerosis (RRMS) in the 96-week, phase III, double-blind, placebo-controlled CLARITY study

Journal of the Neurological Sciences ◽

10.1016/s0022-510x(09)70457-5 ◽

2009 ◽

Vol 285 ◽

pp. S114

Author(s):

G. Giovannoni ◽

G. Comi ◽

S. Cook ◽

K. Rammohan ◽

P. Rieckmann ◽

...

Keyword(s):

Multiple Sclerosis ◽

Clinical Outcomes ◽

Oral Treatment ◽

Phase Iii ◽

Double Blind ◽

Double Blind Placebo ◽

Short Course ◽

Relapsing Remitting ◽

Interferon beta-1b is effective in relapsing-remitting multiple-sclerosis: II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial

Neurology ◽

10.1212/01.wnl.0000407006.93844.fb ◽

2011 ◽

Vol 77 (15) ◽

pp. 1431-1431

Author(s):

D. W. Paty ◽

D. K. B. Li ◽

Keyword(s):

Multiple Sclerosis ◽

Interferon Beta ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Relapsing Remitting ◽

Pharmacokinetics and pharmacodynamics of PEGylated interferon beta-1a in patients with relapsing-remitting multiple sclerosis in the randomized double-blind placebo-controlled study

10.26226/morressier.5b719e465aff74008ae4ca68 ◽

2018 ◽

Author(s):

Arina Zinkina-Orikhan

Keyword(s):

Multiple Sclerosis ◽

Interferon Beta ◽

Pegylated Interferon ◽

Controlled Study ◽

Pharmacokinetics And Pharmacodynamics ◽

Double Blind ◽

Double Blind Placebo ◽

Relapsing Remitting ◽

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial

Neurology ◽

10.1212/wnl.43.4.655 ◽

1993 ◽

Vol 43 (4) ◽

pp. 655-655 ◽

Cited By ~ 1711

Author(s):

Keyword(s):

Multiple Sclerosis ◽

Interferon Beta ◽

Controlled Trial ◽

Clinical Results ◽

Double Blind ◽

Double Blind Placebo ◽

Relapsing Remitting ◽